

Remarks

Claims 1-4, 6-8, and 10-12 are pending.

Claims 5, 9 and 13 have been canceled. Applicants retain the right to pursue the subject matter of these claims in other patent applications.

Claims 1-4 and 6-8 have been allowed.

Claims 5 and 9-13 have been rejected.

Claim 10 has been amended to change dependency to claim 1.

Rejections Under 35 U.S.C. §112, First Paragraph


Claims 5 and 9-13 stand rejected under 35 U.S.C. §112, first paragraph, for allegedly containing subject matter not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention with respect to the availability of the strain ATCC 35203. Claims 5, 9 and 13, which contain reference to a strain ATCC 35203, have been canceled, thus rendering the present rejection moot.

Claims 10-12, which previously were dependent to canceled claim 9, now are dependent to claim 1. Claims 10-12 are believed to be in condition for allowance.

The Examiner is invited to contact the undersigned if it is believed that a telephonic communication would expedite the prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
Date: *November 14, 2006*


Gary D. Greenblatt, Ph.D.
Agent for Applicant
Reg. No. 47,609
Phone: 609-252-3850